PDCD1 and non-small cell lung carcinoma: In clinical validation, 50 patients with NSCLC with high bTMB (≥ 6 mut/Mb) was associated with prolonged mPFS and higher ORR than patients with low bTMB (< 6 mut/Mb) (mPFS not reach vs 2.9 m; ORR 39.3% vs 9.1%) when treated with anti-PD-1/PD-L1 therapies [96] (see Table 5).